Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

Cited In for PubMed (Select 7548469)

1.

Prenatal choline and the development of schizophrenia.

Freedman R, Ross RG.

Shanghai Arch Psychiatry. 2015 Apr 25;27(2):90-102. doi: 10.11919/j.issn.1002-0829.215006. Review.

2.

Evaluation of [(18)F]-(-)-norchlorofluorohomoepibatidine ([(18)F]-(-)-NCFHEB) as a PET radioligand to image the nicotinic acetylcholine receptors in non-human primates.

Bois F, Gallezot JD, Zheng MQ, Lin SF, Esterlis I, Cosgrove KP, Carson RE, Huang Y.

Nucl Med Biol. 2015 Jun;42(6):570-7. doi: 10.1016/j.nucmedbio.2014.08.003. Epub 2014 Aug 8.

PMID:
25858513
3.

Could vagus nerve stimulation target hippocampal hyperactivity to improve cognition in schizophrenia?

Smucny J, Visani A, Tregellas JR.

Front Psychiatry. 2015 Mar 24;6:43. doi: 10.3389/fpsyt.2015.00043. eCollection 2015. Review. No abstract available.

4.

The human CHRNA7 and CHRFAM7A genes: A review of the genetics, regulation, and function.

Sinkus ML, Graw S, Freedman R, Ross RG, Lester HA, Leonard S.

Neuropharmacology. 2015 Sep;96(Pt B):274-88. doi: 10.1016/j.neuropharm.2015.02.006. Epub 2015 Feb 19. Review.

PMID:
25701707
5.

Inside-out neuropharmacology of nicotinic drugs.

Henderson BJ, Lester HA.

Neuropharmacology. 2015 Sep;96(Pt B):178-93. doi: 10.1016/j.neuropharm.2015.01.022. Epub 2015 Feb 4. Review.

PMID:
25660637
6.

R-(+) and S-(-) isomers of cotinine augment cholinergic responses in vitro and in vivo.

Terry AV Jr, Callahan PM, Bertrand D.

J Pharmacol Exp Ther. 2015 Feb;352(2):405-18. doi: 10.1124/jpet.114.219881. Epub 2014 Dec 12.

PMID:
25503389
7.

Small effects of smoking on visual spatiotemporal processing.

Kunchulia M, Pilz KS, Herzog MH.

Sci Rep. 2014 Dec 4;4:7316. doi: 10.1038/srep07316.

8.

Nicotine effects in adolescence and adulthood on cognition and α₄β₂-nicotinic receptors in the neonatal ventral hippocampal lesion rat model of schizophrenia.

Berg SA, Sentir AM, Bell RL, Engleman EA, Chambers RA.

Psychopharmacology (Berl). 2015 May;232(10):1681-92. doi: 10.1007/s00213-014-3800-2. Epub 2014 Nov 13.

PMID:
25388292
9.

AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation.

Feuerbach D, Pezous N, Weiss M, Shakeri-Nejad K, Lingenhoehl K, Hoyer D, Hurth K, Bilbe G, Pryce CR, McAllister K, Chaperon F, Kucher K, Johns D, Blaettler T, Lopez Lopez C.

Br J Pharmacol. 2015 Mar;172(5):1292-304. doi: 10.1111/bph.13001. Epub 2015 Jan 12.

PMID:
25363835
10.

Nicotine usage is associated with elevated processing speed, spatial working memory, and visual learning performance in youth at ultrahigh-risk for psychosis.

Gupta T, Mittal VA.

Psychiatry Res. 2014 Dec 15;220(1-2):687-90. doi: 10.1016/j.psychres.2014.07.085. Epub 2014 Aug 13.

PMID:
25190344
11.

Cotinine halts the advance of Alzheimer's disease-like pathology and associated depressive-like behavior in Tg6799 mice.

Patel S, Grizzell JA, Holmes R, Zeitlin R, Solomon R, Sutton TL, Rohani A, Charry LC, Iarkov A, Mori T, Echeverria Moran V.

Front Aging Neurosci. 2014 Jul 23;6:162. doi: 10.3389/fnagi.2014.00162. eCollection 2014.

12.

Adjunctive treatment for cognitive impairment in patients with chronic schizophrenia: a double-blind, placebo-controlled study.

Zhu W, Zhang Z, Qi J, Liu F, Chen J, Zhao J, Guo X.

Neuropsychiatr Dis Treat. 2014 Jul 14;10:1317-23. doi: 10.2147/NDT.S64189. eCollection 2014.

13.

Meta-analyses of 10 polymorphisms associated with the risk of schizophrenia.

Dai D, Wang Y, Yuan J, Zhou X, Jiang D, Li J, Zhang Y, Yin H, Duan S.

Biomed Rep. 2014 Sep;2(5):729-736. Epub 2014 Jun 30.

14.

Cortical parvalbumin GABAergic deficits with α7 nicotinic acetylcholine receptor deletion: implications for schizophrenia.

Lin H, Hsu FC, Baumann BH, Coulter DA, Anderson SA, Lynch DR.

Mol Cell Neurosci. 2014 Jul;61:163-75. doi: 10.1016/j.mcn.2014.06.007. Epub 2014 Jun 28.

15.

Diverse strategies targeting α7 homomeric and α6β2* heteromeric nicotinic acetylcholine receptors for smoking cessation.

Brunzell DH, McIntosh JM, Papke RL.

Ann N Y Acad Sci. 2014 Oct;1327:27-45. doi: 10.1111/nyas.12421. Epub 2014 Apr 14. Review.

PMID:
24730978
16.

The therapeutic promise of positive allosteric modulation of nicotinic receptors.

Uteshev VV.

Eur J Pharmacol. 2014 Mar 15;727:181-5. doi: 10.1016/j.ejphar.2014.01.072. Epub 2014 Feb 12. Review.

17.

Pharmacological Interventions for the MATRICS Cognitive Domains in Schizophrenia: What's the Evidence?

Vingerhoets WA, Bloemen OJ, Bakker G, van Amelsvoort TA.

Front Psychiatry. 2013 Dec 4;4:157. doi: 10.3389/fpsyt.2013.00157. Review.

18.

Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia.

Boggs DL, Carlson J, Cortes-Briones J, Krystal JH, D'Souza DC.

Curr Pharm Des. 2014;20(31):5077-92. Review.

19.

Smoking behaviour and mental health disorders--mutual influences and implications for therapy.

Minichino A, Bersani FS, Calò WK, Spagnoli F, Francesconi M, Vicinanza R, Delle Chiaie R, Biondi M.

Int J Environ Res Public Health. 2013 Oct 10;10(10):4790-811. doi: 10.3390/ijerph10104790. Review.

20.

Association of the Nicotinic Receptor α7 Subunit Gene (CHRNA7) with Schizophrenia and Visual Backward Masking.

Bakanidze G, Roinishvili M, Chkonia E, Kitzrow W, Richter S, Neumann K, Herzog MH, Brand A, Puls I.

Front Psychiatry. 2013 Oct 22;4:133. doi: 10.3389/fpsyt.2013.00133. eCollection 2013.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk